ChromaDex Corporation (CDXC) Hit a 52 Week High, Can the Run Continue?

Company Performance - ChromaDex (CDXC) shares have increased by 72.9% over the past month, reaching a new 52-week high of $6.18 [1] - Since the beginning of the year, ChromaDex has gained 301.4%, significantly outperforming the Zacks Medical sector's 3.1% increase and the -2.3% return of the Zacks Medical - Biomedical and Genetics industry [1] Earnings and Valuation - ChromaDex has consistently exceeded earnings expectations, reporting an EPS of$ 0.02 against a consensus estimate of $0.01 in its latest earnings report on October 31, 2024, and beating revenue estimates by 7.93% [2] - The stock currently trades at a valuation of 246X current fiscal year EPS estimates, which is a premium compared to the peer industry average of 24.1X [5] Zacks Rank and Style Scores - ChromaDex holds a Zacks Rank of 1 (Strong Buy) due to rising earnings estimates, indicating strong potential for further gains [6] - The company has a Value Score of D, while its Growth and Momentum Scores are both A, resulting in a combined VGM Score of B [5][6] Industry Comparison - MiMedx Group, Inc (MDXG) is a notable competitor, holding a Zacks Rank of 2 (Buy) with strong earnings performance, having beaten consensus estimates by 40% last quarter [7][8] - The Medical - Biomedical and Genetics industry is positioned in the top 38% of all industries, suggesting favorable conditions for both ChromaDex and MiMedx Group [9]